Estonija - estonščina - Ravimiamet

g.l. pharma gmbh - valproehape - suukaudsed tilgad, lahus - 300mg 1ml 100ml 1tk

Estonija - estonščina - Ravimiamet

g.l. pharma gmbh - valproehape - gastroresistentne pehmekapsel - 150mg 100tk

Estonija - estonščina - Ravimiamet

g.l. pharma gmbh - valproehape - süste-/infusioonilahus - 100mg 1ml 5ml 5tk

Estonija - estonščina - Ravimiamet

g.l. pharma gmbh - valproehape - toimeainet prolongeeritult vabastav tablett - 500mg 50tk

Estonija - estonščina - Ravimiamet

g.l. pharma gmbh - valproehape - siirup - 50mg 1ml 100ml 1tk

Estonija - estonščina - Ravimiamet

ideal trade links uab - valproehape - toimeainet prolongeeritult vabastav tablett - 500mg 100tk; 500mg 30tk

Evropska unija - estonščina - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - muud antineoplastilised ained - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Estonija - estonščina - Ravimiamet

medochemie limited - klaritromütsiin - õhukese polümeerikattega tablett - 500mg 12tk; 500mg 20tk

Estonija - estonščina - Ravimiamet

sun pharmaceutical industries europe b.v. - klaritromütsiin - õhukese polümeerikattega tablett - 500mg 10tk

Estonija - estonščina - Ravimiamet

medochemie limited - klaritromütsiin - õhukese polümeerikattega tablett - 250mg 14tk; 250mg 12tk